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Background
A randomized, double-blind, placebo-controlled study
was performed to evaluate the effects of oral BCAA and
leucine supplementation combined with an acute bout of
lower extremity resistance exercise (RE) on the phosphor-
ylation/activation states of mTOR and 4EBP1.
Methods
30 fasted, recreationally trained males (22.5 yrs; 83.1 kg;
178.4 cm) consumed 120 mg/kg/bw of BCAA, 60 mg/kg/
bw of leucine, or a placebo. The supplements were con-
sumed in three equal doses at 30 minutes before RE,
immediately prior to RE, and immediately post RE. The
participants completed 4 sets of both leg press and knee
extension at 80% of their 1 RM to failure (~8–12 reps).
Rest periods of 2.5 minutes were given between both sets
and exercises. Percutaneous muscle biopsies of the vastus
lateralis were obtained at: baseline, and 30 minutes, 2
hours, and 6 hours post RE. The phosphorylated states of
both mTOR and 4E-BP1 were assessed through the use of
an ELISA with a primary antibody specific to phosphor-
ylated mTOR [pS2448] and a phosphoELISA kit for phos-
phorylated 4E-BP1 [pT46], respectively. Other serum and
muscle variables were analyzed as part of a greater, overall
study, but only the phosphorylated mTOR and 4E-BP1 are
reported in this abstract. Delta values of mTOR and 4E-
BP1 were analyzed using a 3 (group) × 4 (time) repeated
measures MANOVA. Separate ANOVAs for each criterion
variable were utilized as follow-up tests. Significant main
effects were determined Bonferroni post-hoc tests. Signif-
icant interactions discovered in the ANOVAs were
assessed by independent samples T-tests. SPSS version
15.0 was utilized throughout this analysis.
Results
There was no main effect for group, time or group × time
interaction for phosphorylated mTOR. In regards to phos-
phorylated 4E-BP1, no main effect for time was observed.
However, a significant group main effect for 4E-BP1 was
observed (p = 0.002). Bonferroni post-hoc analysis dem-
onstrated that both the BCAA group (p = 0.002) and the
leucine group (p = .037) were significantly greater than
the placebo group in regards to phosphorylated 4E-BP1.
Additionally, a group × time interaction for 4E-BP1 was
also observed. Activated 4E-BP1 was significantly greater
in the BCAA group (p = 0.001) and leucine group (p =
.037) at 2 hours post RE as compared to the placebo. At 6
hours post RE, 4E-BP1 activation was greater in the BCAA
group as compared to both the placebo (p = 0.022) and
leucine groups (p = 0.041).
Conclusion
Both leucine and BCAA supplementation, combined with
an acute bout of lower extremity RE, led to greater levels
of phosphorylated 4E-BP1, as compared to a placebo, 2
hours following RE. Furthermore, BCAA group led to sig-
nificantly greater levels of activated 4E-BP1 when com-
pared to both the placebo and leucine at 6 hours post RE.
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These findings suggest that the other two BCAAs (isoleu-
cine and valine) may contribute to greater activation states
of 4E-BP1 above and beyond that of leucine alone. Lastly,
in the current study, neither BCAA nor leucine supple-
mentation did not have a significant effect on the phos-
phorylation state of the cell signaling protein, mTOR.